Nano Science and Technology Institute

S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies

Singapore’s S*BIO Pte Ltd announced it has dosed the first 10 patients in a Phase 2 clinical trial in the U.S. and Canada

Story content courtesy of S*BIO Pte Ltd, Singapore

The multi-center, open-label, study is designed to primarily evaluate the efficacy and safety of SB1518 in patients with advanced lymphoid malignancies in five sites including M.D. Anderson, Rochester University, Cornell University, University of Nebraska, and British Columbia Cancer Center. Secondary objectives include duration of response and progression-free survival.

“The development of SB1518 in a second indication is a significant milestone in the clinical advancement of our lead JAK2 inhibitor,” said Dr. Jan-Anders Karlsson, CEO of S*BIO. “The initiation of this Phase 2 trial demonstrates our commitment in advancing this best-in-class compound and addressing the unmet medical need for an effective treatment of lymphoma.”

S*BIO investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, and Novartis Bioventures.

RSS feed of Nano World News

↑ Back to Nano World News™

© 2014 Nano Science and Technology Institute. All Rights Reserved.
Terms of Use | Privacy Policy | Contact Us | Site Map

Fatal error: Call to undefined function share_scripts() in /export/home/apache/httpd-nrc/docs/news/item.html on line 36